Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2

References

• Rodriguez-Guerra M, Jadhav P, Vittorio TJ. Current treatment in COVID-19 disease: a rapid review. Drugs Context. 2021;10:1–8. doi:10.7573/dic.2020-10-3
   Google Scholar
• Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls; 2022.
   Google Scholar
• Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: a review. Eur J Pharmacol. 2020;883:173372. doi:10.1016/j.ejphar.2020.173372
   PubMed Web of Science ®Google Scholar
• Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic review on repurposing use of favipiravir against SARS-CoV-2. Mymensingh Med J. 2020;29(3):747–754.
   PubMedGoogle Scholar
• Perveen RA, Nasir M, Talha KA, Selina F, Islam MA. Systematic review on current antiviral therapy in COVID-19 pandemic. Med J Malaysia. 2020;75(6):710–716.
   PubMedGoogle Scholar
• Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192–206. doi:10.1111/joim.13091
   PubMed Web of Science ®Google Scholar
• Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28. doi:10.1038/s41541-021-00292-w
   PubMed Web of Science ®Google Scholar
• Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021;7(4):512–533. doi:10.1021/acscentsci.1c00120
   PubMed Web of Science ®Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683. doi:10.1021/acscentsci.0c00489
   PubMed Web of Science ®Google Scholar
• Senger MR, Evangelista TCS, Dantas RF, et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz. 2020;115:e200254. doi:10.1590/0074-02760200254
   PubMed Web of Science ®Google Scholar
• Simabuco FM, Tamura RE, Pavan ICB, Morale MG, Ventura AM. Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. Genet Mol Biol. 2020;44(1 Suppl 1):e20200212. doi:10.1590/1678-4685-gmb-2020-0212
   PubMed Web of Science ®Google Scholar
• Pluskota-Karwatka D, Hoffmann M, Barciszewski J. Reducing SARS-CoV-2 pathological protein activity with small molecules. J Pharm Anal. 2021;11(4):383–397. doi:10.1016/j.jpha.2021.03.012
   PubMed Web of Science ®Google Scholar
• Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res. 2013;100(1):286–295. doi:10.1016/j.antiviral.2013.08.015
   PubMed Web of Science ®Google Scholar
• Dolgin E. The race for antiviral drugs to beat COVID - and the next pandemic. Nature. 2021;592(7854):340–343. doi:10.1038/d41586-021-00958-4
   PubMed Web of Science ®Google Scholar
• Kabinger F, Stiller C, Schmitzova J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–746. doi:10.1038/s41594-021-00651-0
   PubMed Web of Science ®Google Scholar
• Posthuma CC, Te Velthuis AJW, Snijder EJ. Nidovirus RNA polymerases: complex enzymes handling exceptional RNA genomes. Virus Res. 2017;234:58–73. doi:10.1016/j.virusres.2017.01.023
   PubMed Web of Science ®Google Scholar
• Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325–337. doi:10.1080/13543776.2021.1880568
   PubMed Web of Science ®Google Scholar
• Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021;12(1):279. doi:10.1038/s41467-020-20542-0
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044
   PubMed Web of Science ®Google Scholar
• Sticher ZM, Lu G, Mitchell DG, et al. Analysis of the potential for N (4)-hydroxycytidine to inhibit mitochondrial replication and function. Antimicrob Agents Chemother. 2020;64(2). doi:10.1128/AAC.01719-19
   Web of Science ®Google Scholar
• Eng H, Dantonio AL, Kadar EP, et al. Disposition of PF-07321332 (Nirmatrelvir), an orally bioavailable inhibitor of SARS-CoV-2 3CL protease, across animals and humans. Drug Metab Dispos. 2022;DMD-AR-2021-000801. doi:10.1124/dmd.121.000801
   Web of Science ®Google Scholar
• Mahase E. Covid-19: pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. MBJ. 2021;375:n2713.
   PubMed Web of Science ®Google Scholar
• Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015;17(1):37–46.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368(6489):409–412. doi:10.1126/science.abb3405
   PubMed Web of Science ®Google Scholar
• Wong JP, Damania B. SARS-CoV-2 dependence on host pathways. Science. 2021;371(6532):884–885. doi:10.1126/science.abg6837
   PubMed Web of Science ®Google Scholar
• Goyal B, Goyal D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb Sci. 2020;22(6):297–305. doi:10.1021/acscombsci.0c00058
   PubMed Web of Science ®Google Scholar
• Mariano G, Farthing RJ, Lale-Farjat SLM, Bergeron JRC. Structural characterization of SARS-CoV-2: where we are, and where we need to be. Front Mol Biosci. 2020;7:605236. doi:10.3389/fmolb.2020.605236
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707–708. doi:10.1001/jama.2020.0757
   PubMed Web of Science ®Google Scholar
• Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci. 2020;41(11):815–829. doi:10.1016/j.tips.2020.07.004
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18. doi:10.12932/AP-200220-0773
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. doi:10.1038/s41577-021-00542-x
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185–1191. doi:10.1038/s41564-020-00789-5
   PubMed Web of Science ®Google Scholar
• Razonable RR, Pawlowski C, O’Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 2021;40:101102. doi:10.1016/j.eclinm.2021.101102
   PubMedGoogle Scholar
• Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021. doi:10.1093/cid/ciab912
   Web of Science ®Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Engl J Med. 2021;385(15):1382–1392. doi:10.1056/NEJMoa2102685
   PubMed Web of Science ®Google Scholar
• Quiros-Roldan E, Amadasi S, Zanella I, et al. Monoclonal antibodies against SARS-CoV-2: current scenario and future perspectives. Pharmaceuticals. 2021;14(12). doi:10.3390/ph14121272
   Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi:10.1056/NEJMoa2107934
   PubMed Web of Science ®Google Scholar
• Orders M. An EUA for sotrovimab for treatment of COVID-19. Med Lett Drugs Ther. 2021;63(1627):97–xx98.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. Hlh Across Speciality Collaboration UK: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi:10.1128/MMBR.05015-11
   PubMed Web of Science ®Google Scholar
• Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. doi:10.1016/j.cyto.2018.01.025
   PubMed Web of Science ®Google Scholar
• D’Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. Targeting the “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol. 2013;20(3):319–327. doi:10.1128/CVI.00636-12
   PubMedGoogle Scholar
• Lancet T. COVID-19: fighting panic with information. Lancet. 2020;395(10224):537. doi:10.1016/S0140-6736(20)30379-2
   PubMed Web of Science ®Google Scholar
• Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017;10(4):365–374. doi:10.1080/17474086.2017.1300522
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000
   PubMed Web of Science ®Google Scholar
• Wujtewicz M, Dylczyk-Sommer A, Aszkielowicz A, Zdanowski S, Piwowarczyk S, Owczuk R. COVID-19 - what should anaethesiologists and intensivists know about it? Anaesthesiol Intensive Ther. 2020;52(1):34–41. doi:10.5114/ait.2020.93756
   PubMed Web of Science ®Google Scholar
• Ghahramani S, Tabrizi R, Lankarani KB, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):30. doi:10.1186/s40001-020-00432-3
   PubMed Web of Science ®Google Scholar
• Cron EM. Cytokine storm syndrome. 2019.
   Google Scholar
• Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e436. doi:10.1016/S2665-9913(20)30120-X
   PubMedGoogle Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2
   PubMed Web of Science ®Google Scholar
• Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283–2285. doi:10.1002/jmv.25948
   PubMed Web of Science ®Google Scholar
• Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028. doi:10.1515/cclm-2020-0369
   PubMed Web of Science ®Google Scholar
• Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–136 e124. doi:10.1016/j.jaci.2020.05.008
   PubMed Web of Science ®Google Scholar
• Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5(7):751–753. doi:10.1001/jamacardio.2020.1105
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–818. doi:10.1001/jamacardio.2020.1017
   PubMed Web of Science ®Google Scholar
• Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020;8(1):13–17. doi:10.14218/JCTH.2020.00019
   PubMed Web of Science ®Google Scholar
• Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390–391. doi:10.1016/j.pcad.2020.03.001
   PubMed Web of Science ®Google Scholar
• Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi:10.1001/jamaneurol.2020.1127
   PubMed Web of Science ®Google Scholar
• Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020;40(6):1321–1326. doi:10.1111/liv.14449
   PubMed Web of Science ®Google Scholar
• Thachil J, Cushman M, Srivastava A. A proposal for staging COVID-19 coagulopathy. Res Pract Thromb Haemost. 2020;4(5):731–736. doi:10.1002/rth2.12372
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–1561. doi:10.1111/jth.14849
   PubMed Web of Science ®Google Scholar
• Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017;69(6):1135–1143. doi:10.1002/art.40071
   PubMed Web of Science ®Google Scholar
• Wang X, He Z, Zhao X. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review). Exp Ther Med. 2021;21(4):319. doi:10.3892/etm.2021.9750
   PubMed Web of Science ®Google Scholar
• Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020;8(8):822–830. doi:10.1016/S2213-2600(20)30267-8
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Guimaraes PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;385(5):406–415. doi:10.1056/NEJMoa2101643
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30. doi:10.1056/NEJMoa2030340
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Lancent. 2021;397:1637–1645.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516. doi:10.1056/NEJMoa2028700
   PubMed Web of Science ®Google Scholar
• Tatham KC, Shankar-Hari M, Arabi YM. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med. 2021;47(11):1315–1318. doi:10.1007/s00134-021-06540-w
   PubMed Web of Science ®Google Scholar
• Khan FA, Stewart I, Fabbri L, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021;76(9):907–919. doi:10.1136/thoraxjnl-2020-215266
   PubMed Web of Science ®Google Scholar
• Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–1023. doi:10.1016/j.immuni.2019.03.026
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–1247. doi:10.7150/ijbs.4989
   PubMed Web of Science ®Google Scholar
• Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731–733. doi:10.1016/j.immuni.2020.04.003
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53:368–370. doi:10.1016/j.jmii.2020.03.005
   PubMedGoogle Scholar
• Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462(1):1–13. doi:10.1042/BJ20140712
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi:10.1016/j.clim.2020.108393
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. doi:10.1016/S1473-3099(20)30132-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Song Q, Huang W, et al. A virus-induced conformational switch of STAT1-STAT2 dimers boosts antiviral defenses. Cell Res. 2021;31(2):206–218. doi:10.1038/s41422-020-0386-6
   PubMed Web of Science ®Google Scholar
• Deng JC, Zeng X, Newstead M, et al. STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection. J Immunol. 2004;173(6):4075–4083. doi:10.4049/jimmunol.173.6.4075
   PubMed Web of Science ®Google Scholar
• Mehrpouya-Bahrami P, Moriarty AK, De Melo P, et al. STAT4 is expressed in neutrophils and promotes antimicrobial immunity. JCI Insight. 2021;6(14):e141326. doi:10.1172/jci.insight.141326
   PubMed Web of Science ®Google Scholar
• Passerini L, Allan SE, Battaglia M, et al. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol. 2008;20(3):421–431. doi:10.1093/intimm/dxn002
   PubMed Web of Science ®Google Scholar
• Iff J, Wang W, Sajic T, et al. Differential proteomic analysis of STAT6 knockout mice reveals new regulatory function in liver lipid homeostasis. J Proteome Res. 2009;8(10):4511–4524. doi:10.1021/pr9003272
   PubMed Web of Science ®Google Scholar
• Kang SG, Lee SE, Choi MJ, et al. Th2 cytokines increase the expression of fibroblast growth factor 21 in the liver. Cells. 2021;10(6):1298. doi:10.3390/cells10061298
   PubMed Web of Science ®Google Scholar
• Tsao CH, Shiau MY, Chuang PH, Chang YH, Hwang J. Interleukin-4 regulates lipid metabolism by inhibiting adipogenesis and promoting lipolysis. J Lipid Res. 2014;55(3):385–397. doi:10.1194/jlr.M041392
   PubMed Web of Science ®Google Scholar
• Nassal D, Mohta S, Patel N, et al. Regulation of STAT3 phosphorylation through βIV-spectrin interaction and its role in concentric versus eccentric hypertrophy. Circulation. 2021;144:A13911.
   Google Scholar
• Kotyla PJ, Islam MA, Engelmann M. Clinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci. 2020;21(19):7390. doi:10.3390/ijms21197390
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145. doi:10.1038/s41584-021-00726-8
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi:10.1038/s41591-021-01643-9
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi:10.1186/s13075-019-1964-1
   PubMed Web of Science ®Google Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. doi:10.1016/S0140-6736(20)30304-4
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418. doi:10.1016/S2213-2600(21)00331-3
   PubMed Web of Science ®Google Scholar
• Ali H, Salhotra A, Modi B, Nakamura R. Ruxolitinib for the treatment of graft-versus-host disease. Expert Rev Clin Immunol. 2020;16(4):347–359. doi:10.1080/1744666X.2020.1740592
   PubMed Web of Science ®Google Scholar
• Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother. 2012;13(16):2397–2407. doi:10.1517/14656566.2012.732998
   PubMed Web of Science ®Google Scholar
• Stanevich OV, Fomina DS, Bakulin IG, et al. Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study. BMC Infect Dis. 2021;21(1):1277. doi:10.1186/s12879-021-06982-z
   PubMed Web of Science ®Google Scholar
• Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312–332. doi:10.1038/s41375-020-01072-6
   PubMed Web of Science ®Google Scholar
• Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019;25(6):386–393. doi:10.1097/PPO.0000000000000412
   PubMed Web of Science ®Google Scholar
• Roschewski M, Lionakis MS, Sharman JP, et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020;5(48). doi:10.1126/sciimmunol.abd0110
   PubMed Web of Science ®Google Scholar
• Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912–1915. doi:10.1182/blood.2020006288
   PubMed Web of Science ®Google Scholar
• Rada M, Qusairy Z, Massip-Salcedo M, Macip S. Relevance of the Bruton tyrosine kinase as a target for COVID-19 therapy. Mol Cancer Res. 2021;19(4):549–554. doi:10.1158/1541-7786.MCR-20-0814
   PubMed Web of Science ®Google Scholar
• Kifle ZD. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: a review. Metabol Open. 2021;11:100116. doi:10.1016/j.metop.2021.100116
   PubMedGoogle Scholar
• Rezaei M, Babamahmoodi A, Marjani M. Bruton’s tyrosine kinase: a promising target for the treatment of COVID-19. Tanaffos. 2020;19(2):85–88.
   PubMedGoogle Scholar
• Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21. doi:10.1186/s13045-016-0250-9
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. doi:10.1182/bloodadvances.2020004074
   PubMed Web of Science ®Google Scholar
• Markham A, Dhillon S. Acalabrutinib: first global approval. Drugs. 2018;78(1):139–145. doi:10.1007/s40265-017-0852-8
   PubMed Web of Science ®Google Scholar
• Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–e240. doi:10.3747/co.26.4345
   PubMed Web of Science ®Google Scholar
• Horakova O, Kroupova P, Bardova K, et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci Rep. 2019;9(1):6156. doi:10.1038/s41598-019-42531-0
   PubMed Web of Science ®Google Scholar
• Bai B, Chen H. Metformin: a novel weapon against inflammation. Front Pharmacol. 2021;12:622262. doi:10.3389/fphar.2021.622262
   PubMed Web of Science ®Google Scholar
• Hyun B, Shin S, Lee A, et al. Metformin down-regulates TNF-alpha secretion via suppression of scavenger receptors in macrophages. Immun Netw. 2013;13(4):123–132. doi:10.4110/in.2013.13.4.123
   PubMedGoogle Scholar
• El-Arabey AA, Abdalla M. Metformin and COVID-19: a novel deal of an old drug. J Med Virol. 2020;92(11):2293–2294. doi:10.1002/jmv.25958
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gwilt M. Diabetes, metformin and the clinical course of Covid-19: outcomes, mechanisms and suggestions on the therapeutic use of metformin. Front Pharmacol. 2022;13:784459. doi:10.3389/fphar.2022.784459
   PubMed Web of Science ®Google Scholar
• Bramante CT, Ingraham NE, Murray TA, et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1):e34–e41. doi:10.1016/S2666-7568(20)30033-7
   PubMedGoogle Scholar
• Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM, Hajikhani B, Mirsaeidi M, Nasiri MJ. The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: a systematic review. Front Endocrinol. 2021;12:645194. doi:10.3389/fendo.2021.645194
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–254. doi:10.1038/sj.bjp.0706736
   PubMed Web of Science ®Google Scholar
• Group TRC. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):12.
   Web of Science ®Google Scholar
• Gordon AC, Mouncey PR, Al-Beidh F, et al.; Investigators R-C. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021;600(7888):204–207. doi:10.1038/d41586-021-03619-8
   PubMed Web of Science ®Google Scholar
• Chen J, Wei GW. Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant. ArXiv. 2022. doi:10.1021/acs.jpclett.2c00469
   Google Scholar
• El-Arabey AA, Abdalla M. In the face of the future, what do we learn from COVID-19? Hum Vaccin Immunother. 2021;17(11):4119–4120. doi:10.1080/21645515.2021.1963174
   PubMed Web of Science ®Google Scholar
• Abdalla M, El-Arabey AA, Jiang X. Are the new SARS-CoV-2 variants resistant against the vaccine? Hum Vaccin Immunother. 2021;17(10):3489–3490. doi:10.1080/21645515.2021.1925503
   PubMed Web of Science ®Google Scholar
• Abdalla M, El-Arabey AA, Jiang X. What are the challenges faced by COVID-19 vaccines? Expert Rev Vaccines. 2022;21(1):5–7. doi:10.1080/14760584.2022.2008245
   PubMed Web of Science ®Google Scholar
• Nasir M, Talha KA, Islam T, Saha SK, Selina F, Parveen RA. Use of remdesivir in the management of COVID-19: a systematic review on current evidences. Mymensingh Med J. 2020;29(2):481–487.
   PubMedGoogle Scholar